首页 | 本学科首页   官方微博 | 高级检索  
     

苏黄止咳胶囊联合茶碱缓释片治疗哮喘急性发作的临床研究
引用本文:张倩,白黎峰,郑院青,杨咪乐. 苏黄止咳胶囊联合茶碱缓释片治疗哮喘急性发作的临床研究[J]. 现代药物与临床, 2022, 37(6): 1274-1278
作者姓名:张倩  白黎峰  郑院青  杨咪乐
作者单位:平煤神马医疗集团总医院 呼吸与危重症医学科, 河南 平顶山 467000
基金项目:平顶山市科技计划项目(2019-152)
摘    要:目的 探讨苏黄止咳胶囊联合茶碱缓释片治疗哮喘急性发作的临床效果。方法 选取2018年8月—2021年8月平煤神马医疗集团总医院收治的86例哮喘急性发作患者,运用随机数字表法分成对照组和治疗组,每组各43例。对照组口服茶碱缓释片,1片/次,2次/d。治疗组在对照组基础上口服苏黄止咳胶囊,3粒/次,3次/d。两组患者均治疗14 d。观察两组临床疗效,比较治疗前后两组患者主要临床症状消失时间,肺通气功能、哮喘控制测试(ACT)问卷评分和简易版哮喘生活质量调查问卷(mini AQLQ)评分,呼出气一氧化氮(FeNO)和血清白细胞介素-33(IL-33)、C反应蛋白(CRP)、血管内皮生长因子(VEGF)水平。结果 治疗后,治疗组总有效率比对照组显著提高(95.35%vs 81.40%,P<0.05)。治疗后,治疗组各项临床症状的消失时间较对照组均显著缩短(P<0.05)。治疗后,两组第1秒用力呼气容积百分比(FEV1%)、呼气峰流速百分比(PEF%)、ACT问卷评分和mini AQLQ评分均显著高于治疗前(P<0.05),且治疗组的改善更显著(P<0.05)。治疗后,两...

关 键 词:苏黄止咳胶囊  茶碱缓释片  哮喘急性发作  肺通气功能  气道炎症  血管内皮生长因子
收稿时间:2021-12-23

Clinical study on Suhuang Zhike Capsules combined with Theophylline Sustained release Tablets in treatment of acute asthma attacks
ZHANG Qian,BAI Li-feng,ZHENG Yuan-qing,YANG Mi-le. Clinical study on Suhuang Zhike Capsules combined with Theophylline Sustained release Tablets in treatment of acute asthma attacks[J]. Drugs & Clinic, 2022, 37(6): 1274-1278
Authors:ZHANG Qian  BAI Li-feng  ZHENG Yuan-qing  YANG Mi-le
Affiliation:Department of Respiratory and Critical Care Medicine, General Hospital of Pingmei Shenma Group, Pingdingshan 467000, China
Abstract:Objective To investigate the clinical effect of Suhuang Zhike Capsules combined with Theophylline Sustained-release Tablets in treatment of acute asthma attacks. Methods Patients (86 cases) with acute asthma attacks in General Hospital of Pingmei Shenma Group from August 2018 to August 2021 were divided into control and treatment group by random number table, and each group had 43 cases. Patients in the control group were po administered with Theophylline Sustained-release Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Suhuang Zhike Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, the disappearance time of main clinical symptoms, pulmonary ventilation function, ACT questionnaire scores and miniAQLQ scores, FeNO and serum IL-33, CRP, and VEGF levels in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (95.35% vs 81.40%, P < 0.05). After treatment, the disappearance time of clinical symptoms in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the scores of FEV1%, PEF%, ACT questionnaire, and miniAQLQ in two groups were significantly higher than those before treatment (P < 0.05), and the improvement in the treatment group was more significant (P < 0.05). After treatment, the levels of FeNO and serum IL-33, CRP, and VEGF in two groups were significantly lower than those before treatment (P < 0.05), especially in the treatment group (P < 0.05). Conclusion The overall curative effect of Suhuang Zhike Capsules combined with Theophylline Sustained-release Tablets in treatment of acute asthma attacks is satisfactory, which can safely and effectively control asthma symptoms, improve pulmonary ventilation function and improve quality of life.
Keywords:Suhuang Zhike Capsules  Theophylline Sustained-release Tablets  acute asthma attacks  lung ventilation function  airway inflammation  VEGF
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号